Key points are not available for this paper at this time.
KEY CLINICAL MESSAGE: Ventricular arrhythmias induced by dasatinib are rare events, but physicians in charge of chronic myeloid leukemia patients should be aware of such potential complications and the need for regular ECG controls during treatment with tyrosine kinase inhibitors.
Spechbach et al. (Wed,) studied this question.